drug_name,disease_category,drug_category,product_name,clinical_trial_title,clinical_trial_start_date,clinical_trial_completion_date,clinical_trial_participants,country,clinical_trial_institution,side_effect,interacts_with,disease_name,company_name,clinical_trial_status,clinical_trial_condition,clinical_trial_address,clinical_trial_main_researcher
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,adenocarcinoma,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,adenocarcinoma,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,adenocarcinoma,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,adenocarcinoma,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,adenocarcinoma,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,adenocarcinoma,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,adenocarcinoma,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,adenocarcinoma,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,adenocarcinoma,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,adenocarcinoma,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,adenocarcinoma,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,adenocarcinoma,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,adenocarcinoma,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,adenocarcinoma,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,adenocarcinoma,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,adenocarcinoma,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,complementary component deficiency,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,complementary component deficiency,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,complementary component deficiency,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,complementary component deficiency,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,complementary component deficiency,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,complementary component deficiency,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,complementary component deficiency,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,complementary component deficiency,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,complementary component deficiency,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,complementary component deficiency,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,complementary component deficiency,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,complementary component deficiency,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,complementary component deficiency,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,complementary component deficiency,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,complementary component deficiency,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,complementary component deficiency,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,igg receptor i,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,igg receptor i,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,igg receptor i,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,igg receptor i,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, phagocytic,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, phagocytic,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, phagocytic,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, phagocytic,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, familial deficiency of,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, familial deficiency of,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, familial deficiency of,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, familial deficiency of,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,igg receptor i,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,igg receptor i,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,igg receptor i,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,igg receptor i,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, phagocytic,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, phagocytic,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, phagocytic,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, phagocytic,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, familial deficiency of,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, familial deficiency of,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, familial deficiency of,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, familial deficiency of,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,igg receptor i,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,igg receptor i,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,igg receptor i,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,igg receptor i,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, phagocytic,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, phagocytic,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, phagocytic,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, phagocytic,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, familial deficiency of,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, familial deficiency of,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, familial deficiency of,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, familial deficiency of,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,igg receptor i,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,igg receptor i,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,igg receptor i,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,igg receptor i,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, phagocytic,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, phagocytic,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, phagocytic,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, phagocytic,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, familial deficiency of,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, familial deficiency of,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, familial deficiency of,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, familial deficiency of,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,lupus erythematosus,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,lupus erythematosus,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,lupus erythematosus,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,lupus erythematosus,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,lupus erythematosus,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,lupus erythematosus,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,lupus erythematosus,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,lupus erythematosus,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,lupus erythematosus,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,lupus erythematosus,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,lupus erythematosus,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,lupus erythematosus,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,lupus erythematosus,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,lupus erythematosus,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,lupus erythematosus,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,lupus erythematosus,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,lymphoma,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,lymphoma,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,lymphoma,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,lymphoma,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,lymphoma,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,lymphoma,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,lymphoma,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,lymphoma,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,lymphoma,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,lymphoma,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,lymphoma,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,lymphoma,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,lymphoma,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,lymphoma,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,lymphoma,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,lymphoma,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,neutropenia,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,neutropenia,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,neutropenia,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,neutropenia,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,neutropenia,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,neutropenia,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,neutropenia,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,neutropenia,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,neutropenia,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,neutropenia,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,neutropenia,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,neutropenia,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,neutropenia,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,neutropenia,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,neutropenia,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,neutropenia,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,nonsmall cell lung cancer,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,nonsmall cell lung cancer,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,nonsmall cell lung cancer,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,nonsmall cell lung cancer,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,nonsmall cell lung cancer,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,nonsmall cell lung cancer,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,nonsmall cell lung cancer,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,nonsmall cell lung cancer,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,nonsmall cell lung cancer,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,nonsmall cell lung cancer,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,nonsmall cell lung cancer,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,nonsmall cell lung cancer,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,nonsmall cell lung cancer,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,nonsmall cell lung cancer,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,nonsmall cell lung cancer,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,nonsmall cell lung cancer,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,viral infection,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,viral infection,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,viral infection,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,viral infection,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,viral infection,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,viral infection,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,viral infection,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,viral infection,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,viral infection,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,viral infection,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,viral infection,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,viral infection,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,viral infection,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,viral infection,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,viral infection,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,viral infection,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,adenocarcinoma of lung,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,adenocarcinoma of lung,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,adenocarcinoma of lung,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,adenocarcinoma of lung,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, 211980,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, 211980,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, 211980,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, 211980,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,adenocarcinoma of lung,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,adenocarcinoma of lung,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,adenocarcinoma of lung,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,adenocarcinoma of lung,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, 211980,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, 211980,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, 211980,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, 211980,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,adenocarcinoma of lung,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,adenocarcinoma of lung,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,adenocarcinoma of lung,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,adenocarcinoma of lung,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, 211980,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, 211980,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, 211980,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, 211980,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,adenocarcinoma of lung,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,adenocarcinoma of lung,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,adenocarcinoma of lung,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,adenocarcinoma of lung,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, response to tyrosine kinase inhibitor in,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, 211980,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, 211980,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, 211980,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, 211980,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,c1q deficiency,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,c1q deficiency,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,c1q deficiency,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,c1q deficiency,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, type a,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, type a,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, type a,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, type a,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,c1q deficiency,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,c1q deficiency,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,c1q deficiency,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,c1q deficiency,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, type a,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, type a,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, type a,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, type a,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,c1q deficiency,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,c1q deficiency,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,c1q deficiency,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,c1q deficiency,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, type a,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, type a,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, type a,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, type a,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,c1q deficiency,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,c1q deficiency,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,c1q deficiency,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,c1q deficiency,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, type a,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, type a,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, type a,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, type a,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, type b,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, type b,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, type b,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, type b,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, type b,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, type b,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, type b,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, type b,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, type b,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, type b,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, type b,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, type b,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, type b,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, type b,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, type b,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, type b,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,c1s deficiency,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,c1s deficiency,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,c1s deficiency,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,c1s deficiency,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, isolated,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, isolated,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, isolated,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, isolated,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,c1s deficiency,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,c1s deficiency,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,c1s deficiency,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,c1s deficiency,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, isolated,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, isolated,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, isolated,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, isolated,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,c1s deficiency,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,c1s deficiency,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,c1s deficiency,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,c1s deficiency,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, isolated,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, isolated,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, isolated,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, isolated,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,c1s deficiency,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,c1s deficiency,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,c1s deficiency,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,c1s deficiency,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, isolated,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, isolated,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, isolated,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, isolated,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,lupus nephritis,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,lupus nephritis,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,lupus nephritis,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,lupus nephritis,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, susceptibility to,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, susceptibility to,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, susceptibility to,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, susceptibility to,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,lupus nephritis,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,lupus nephritis,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,lupus nephritis,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,lupus nephritis,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, susceptibility to,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, susceptibility to,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, susceptibility to,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, susceptibility to,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,lupus nephritis,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,lupus nephritis,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,lupus nephritis,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,lupus nephritis,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, susceptibility to,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, susceptibility to,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, susceptibility to,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, susceptibility to,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,lupus nephritis,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,lupus nephritis,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,lupus nephritis,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,lupus nephritis,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, susceptibility to,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, susceptibility to,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, susceptibility to,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,connective tissue disorder,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, susceptibility to,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, progression of,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, progression of,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, progression of,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, progression of,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, progression of,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, progression of,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, progression of,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, progression of,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, progression of,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, progression of,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, progression of,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, progression of,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, progression of,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, progression of,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, progression of,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,cancer,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, progression of,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, alloimmune neonatal,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, alloimmune neonatal,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, alloimmune neonatal,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, alloimmune neonatal,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, alloimmune neonatal,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, alloimmune neonatal,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, alloimmune neonatal,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, alloimmune neonatal,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, alloimmune neonatal,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, alloimmune neonatal,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, alloimmune neonatal,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, alloimmune neonatal,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, alloimmune neonatal,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, alloimmune neonatal,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, alloimmune neonatal,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,hematological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, alloimmune neonatal,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,viral infections,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,viral infections,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,viral infections,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan,viral infections,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, recurrent,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, recurrent,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, recurrent,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,headache,nan, recurrent,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,viral infections,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,viral infections,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,viral infections,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan,viral infections,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, recurrent,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, recurrent,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, recurrent,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,cough,nan, recurrent,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,viral infections,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,viral infections,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,viral infections,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan,viral infections,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, recurrent,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, recurrent,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, recurrent,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,renal failure,nan, recurrent,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,viral infections,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,viral infections,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,viral infections,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan,viral infections,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, recurrent,imclone llc,completed,laryngeal neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, recurrent,imclone llc,completed,laryngeal neoplasms, internal medicine,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, recurrent,imclone llc,completed,mouth neoplasms,university hospital,wolfgang hilbe
cetuximab,immunological,antineoplastic agents,erbitux,immune response on neoadjuvant therapy in non-small-cell lung cancer (nsclc),2007-01-01 00:00:00,2011-06-01 00:00:00,41.0,austria,medical university of vienna,carcinoma,nan, recurrent,imclone llc,completed,mouth neoplasms, internal medicine,wolfgang hilbe
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,headache,nan,interleukin-2 receptor,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,headache,nan, alpha chain,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,headache,nan, deficiency of,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,pain,nan,interleukin-2 receptor,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,pain,nan, alpha chain,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,pain,nan, deficiency of,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,dehydration,nan,interleukin-2 receptor,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,dehydration,nan, alpha chain,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,dehydration,nan, deficiency of,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,vasodilatation,nan,interleukin-2 receptor,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,vasodilatation,nan, alpha chain,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,vasodilatation,nan, deficiency of,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,headache,nan,severe combined immunodeficiency,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,pain,nan,severe combined immunodeficiency,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,dehydration,nan,severe combined immunodeficiency,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,vasodilatation,nan,severe combined immunodeficiency,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,headache,nan,combined immunodeficiency,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,pain,nan,combined immunodeficiency,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,dehydration,nan,combined immunodeficiency,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,vasodilatation,nan,combined immunodeficiency,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,headache,nan, x-linked,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,headache,nan, moderate,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,headache,nan, 312863,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,pain,nan, x-linked,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,pain,nan, moderate,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,pain,nan, 312863,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,dehydration,nan, x-linked,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,dehydration,nan, moderate,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,dehydration,nan, 312863,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,vasodilatation,nan, x-linked,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,vasodilatation,nan, moderate,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,vasodilatation,nan, 312863,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,headache,nan, 300400,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,pain,nan, 300400,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,dehydration,nan, 300400,eisai inc.,,nan,,
denileukin diftitox,immunological,antineoplastic agents,ontak,,unknown,unknown,0.0,,,vasodilatation,nan, 300400,eisai inc.,,nan,,
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,asthma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,asthma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,asthma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,asthma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,asthma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,asthma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,asthma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,asthma,immunex corporation,completed,melanoma,uab dermatology, md
,,,,addition of etanercept and extracorporeal photopheresis (ecp) to standard graft-versus-host disease (gvhd) prophylaxis in stem cell transplant,2009-03-01 00:00:00,2015-09-01 00:00:00,48.0,united states,university of michigan cancer center,nan,nan,,,active,nan,university of michigan cancer center,john levine
,,,,addition of etanercept and extracorporeal photopheresis (ecp) to standard graft-versus-host disease (gvhd) prophylaxis in stem cell transplant,2009-03-01 00:00:00,2015-09-01 00:00:00,48.0,united states,university of michigan cancer center,nan,nan,,,active,nan,university of michigan cancer center, md
,,,,addition of etanercept and extracorporeal photopheresis (ecp) to standard graft-versus-host disease (gvhd) prophylaxis in stem cell transplant,2009-03-01 00:00:00,2015-09-01 00:00:00,48.0,united states,university of michigan cancer center,nan,nan,,, not recruiting,nan,university of michigan cancer center,john levine
,,,,addition of etanercept and extracorporeal photopheresis (ecp) to standard graft-versus-host disease (gvhd) prophylaxis in stem cell transplant,2009-03-01 00:00:00,2015-09-01 00:00:00,48.0,united states,university of michigan cancer center,nan,nan,,, not recruiting,nan,university of michigan cancer center, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,asthma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,asthma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,asthma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,asthma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,asthma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,asthma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,asthma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,asthma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,asthma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,complementary component deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,complementary component deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,dementia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,dementia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,dementia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,dementia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,dementia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,dementia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,dementia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,dementia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,dementia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,dementia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,dementia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,dementia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,dementia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,dementia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,dementia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,dementia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,dementia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,igg receptor i,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,igg receptor i,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, phagocytic,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, phagocytic,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, familial deficiency of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, familial deficiency of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus erythematosus,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus erythematosus,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lymphoma,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lymphoma,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,malaria,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,malaria,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,malaria,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,malaria,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,malaria,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,malaria,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,malaria,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,malaria,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,malaria,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,malaria,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,malaria,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,malaria,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,malaria,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,malaria,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,malaria,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,malaria,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,malaria,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,myocardial infarction,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,myocardial infarction,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,neutropenia,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,neutropenia,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,sepsis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,sepsis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infection,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infection,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 600807,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 600807,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 600807,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 600807,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 600807,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 600807,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 600807,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 600807,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 600807,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 600807,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 600807,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 600807,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 600807,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 600807,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 600807,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 600807,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,respiratory,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 600807,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type a,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type a,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type a,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type a,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type a,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type a,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type a,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type a,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type a,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type a,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type a,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type a,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type a,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type a,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type a,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type a,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type a,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type a,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type a,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type a,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type a,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type a,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type a,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type a,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type a,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type a,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type a,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type a,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1q deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1q deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type a,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type a,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type a,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type a,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type b,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type b,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type b,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type b,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type b,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type b,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type b,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type b,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type b,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type b,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type b,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type b,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type b,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type b,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type b,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type b,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type b,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type b,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type b,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, type b,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type b,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type b,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type b,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, type b,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type b,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type b,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type b,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, type b,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type b,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type b,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type b,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, type b,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, isolated,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, isolated,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, isolated,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, isolated,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, isolated,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, isolated,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, isolated,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, isolated,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, isolated,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, isolated,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, isolated,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, isolated,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, isolated,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, isolated,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1s deficiency,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,c1s deficiency,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, isolated,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, isolated,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, isolated,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, vascular,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, vascular,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, vascular,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, vascular,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, vascular,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, vascular,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, vascular,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, vascular,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, vascular,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, vascular,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, vascular,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, vascular,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, vascular,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, vascular,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, vascular,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, vascular,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, vascular,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus nephritis,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,lupus nephritis,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,connective tissue disorder,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, progression of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, progression of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, progression of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, progression of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, progression of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, progression of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, progression of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, progression of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, progression of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, progression of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, progression of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, progression of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, progression of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, progression of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, progression of,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, progression of,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cancer,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, progression of,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, cerebral,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, cerebral,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 157300,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 157300,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 157300,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 157300,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 157300,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 157300,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 157300,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 157300,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 157300,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, 157300,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 157300,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, 157300,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 157300,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, 157300,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine without aura,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,migraine without aura,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 157300,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 157300,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,neurological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, 157300,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,cardiovascular,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, susceptibility to,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, alloimmune neonatal,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,hematological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, alloimmune neonatal,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,septic shock,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,septic shock,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,antirheumatic agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,abdominal pain,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nausea,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,melanoma,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infections,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan,viral infections,immunex corporation,completed,melanoma,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, recurrent,immunex corporation,completed,psoriasis,uab dermatology, md
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology,boni elewski
etanercept,immunological,immunomodulatory agents,enbrel,can we miss pigmented lesions in psoriasis patients?,2007-09-01 00:00:00,2012-04-01 00:00:00,6.0,united states,university of alabama at birmingham,nan,nan, recurrent,immunex corporation,completed,melanoma,uab dermatology, md
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan,alzheimer disease,imarx therapeutics,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan,alzheimer disease, inc.,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan,alzheimer disease,imarx therapeutics,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan,alzheimer disease, inc.,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan,alzheimer disease,imarx therapeutics,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan,alzheimer disease, inc.,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan,conjunctivitis,imarx therapeutics,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan,conjunctivitis, inc.,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan, ligneous,imarx therapeutics,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan, ligneous, inc.,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan,conjunctivitis,imarx therapeutics,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan,conjunctivitis, inc.,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan, ligneous,imarx therapeutics,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan, ligneous, inc.,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan,conjunctivitis,imarx therapeutics,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan,conjunctivitis, inc.,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan, ligneous,imarx therapeutics,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan, ligneous, inc.,,nan,,
urokinase,hematological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan,plasminogen deficiency,imarx therapeutics,,nan,,
urokinase,hematological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan,plasminogen deficiency, inc.,,nan,,
urokinase,hematological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan,plasminogen deficiency,imarx therapeutics,,nan,,
urokinase,hematological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan,plasminogen deficiency, inc.,,nan,,
urokinase,hematological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan,plasminogen deficiency,imarx therapeutics,,nan,,
urokinase,hematological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan,plasminogen deficiency, inc.,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan, late-onset,imarx therapeutics,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan, late-onset, inc.,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan, susceptibility to,imarx therapeutics,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan, susceptibility to, inc.,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan, 104300,imarx therapeutics,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan, 104300, inc.,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan, late-onset,imarx therapeutics,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan, late-onset, inc.,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan, susceptibility to,imarx therapeutics,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan, susceptibility to, inc.,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan, 104300,imarx therapeutics,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan, 104300, inc.,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan, late-onset,imarx therapeutics,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan, late-onset, inc.,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan, susceptibility to,imarx therapeutics,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan, susceptibility to, inc.,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan, 104300,imarx therapeutics,,nan,,
urokinase,neurological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan, 104300, inc.,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan, 217090,imarx therapeutics,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan, 217090, inc.,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan, 217090,imarx therapeutics,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan, 217090, inc.,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan, 217090,imarx therapeutics,,nan,,
urokinase,ophthamological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan, 217090, inc.,,nan,,
urokinase,hematological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan,plasminogen tochigi disease,imarx therapeutics,,nan,,
urokinase,hematological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,fever,nan,plasminogen tochigi disease, inc.,,nan,,
urokinase,hematological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan,plasminogen tochigi disease,imarx therapeutics,,nan,,
urokinase,hematological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nausea,nan,plasminogen tochigi disease, inc.,,nan,,
urokinase,hematological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan,plasminogen tochigi disease,imarx therapeutics,,nan,,
urokinase,hematological,thrombolytic agents,kinlytic,,unknown,unknown,0.0,,,nan,nan,plasminogen tochigi disease, inc.,,nan,,
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,complementary component deficiency,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,complementary component deficiency,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,complementary component deficiency,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,complementary component deficiency,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,hematological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,glanzmann thrombasthenia,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,hematological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,glanzmann thrombasthenia,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,hematological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,glanzmann thrombasthenia,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,hematological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,glanzmann thrombasthenia,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,igg receptor i,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,igg receptor i,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, phagocytic,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, phagocytic,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, familial deficiency of,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, familial deficiency of,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,igg receptor i,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,igg receptor i,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, phagocytic,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, phagocytic,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, familial deficiency of,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, familial deficiency of,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,connective tissue disorder,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,lupus erythematosus,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,connective tissue disorder,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,lupus erythematosus,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,connective tissue disorder,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,lupus erythematosus,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,connective tissue disorder,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,lupus erythematosus,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,cancer,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,lymphoma,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,cancer,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,lymphoma,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,cancer,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,lymphoma,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,cancer,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,lymphoma,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,hematological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,neutropenia,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,hematological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,neutropenia,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,hematological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,neutropenia,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,hematological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,neutropenia,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,viral infection,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,viral infection,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,viral infection,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,viral infection,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,c1q deficiency,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,c1q deficiency,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, type a,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, type a,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,c1q deficiency,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,c1q deficiency,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, type a,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, type a,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, type b,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, type b,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, type b,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, type b,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,c1s deficiency,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,c1s deficiency,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, isolated,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, isolated,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,c1s deficiency,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan,c1s deficiency,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, isolated,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,immunological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, isolated,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,hematological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, type b,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,hematological,anticoagulants,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, type b,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
abciximab,hematological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, type b,eli lilly and company,completed,nan,cardiothoracic department,prof. anna sonia petronio
abciximab,hematological,antiplatelet agents,reopro,efficacy study on early versus late abciximab administration during primary coronary angioplasty,2006-04-01 00:00:00,2008-12-01 00:00:00,110.0,italy,university of pisa,nan,nan, type b,eli lilly and company,completed,nan, ospedale cisanello,prof. anna sonia petronio
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,gm  pharamceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,gm  pharamceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,myoxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,vertical pharmaceuticals,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,vertical pharmaceuticals,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair, inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,trioxin,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair, inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,physicians total care,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,physicians total care,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,alcon laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,alcon laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,stat rx usa,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cipro hc,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,stat rx usa,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first dukes mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,cutispharma,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,cutispharma,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,first marys mouthwash compounding,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,a-s medication solutions llc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,a-s medication solutions llc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,chain drug consortium,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,premier value,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,chain drug consortium,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,chattem,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,chattem,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,cortizone 10 poison ivy relief pads,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,atherosclerosis,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,atherosclerosis,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,cortisol resistance,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,endocrine,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,cortisol resistance,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,malaria,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,malaria,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,obesity,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,obesity,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, dimished response to antileukotriene treatment in,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 600807,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, dimished response to antileukotriene treatment in,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 600807,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, susceptibility to,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,cardiovascular,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, susceptibility to,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, resistance to,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, 248310,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, resistance to,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,immunological,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, 248310,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, adrenal insufficiency,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate, and red hair,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, adrenal insufficiency,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,family dollar services inc,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,nutritional,anti-inflammatory agents,family wellness hydrocortisone,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine, and red hair,family dollar services inc,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,pramosone e,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,ferndale laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,pramosone e,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma,ferndale laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,pramosone e,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,pramosone e,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,salsalate,asthma, inc.,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,pramosone e,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,ferndale laboratories,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,pramosone e,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma,ferndale laboratories,terminated,nan,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,pramosone e,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc.,terminated,influenza in humans,raymond poincaré hospital,djillali annane
hydrocortisone,respiratory,anti-inflammatory agents,pramosone e,low doses corticosteroids as adjuvant therapy for the treatment of severe h1n1 flu,2010-03-01 00:00:00,2011-12-01 00:00:00,40.0,france,university of versailles,nan,midodrine,asthma, inc.,terminated,nan,raymond poincaré hospital,djillali annane
